14 unknown, 11 recruiting, 10 not yet recruiting, 9 completed. 41 Phase 2, 9 Phase 1, 9 Phase 3.
Follow famitinib: new trials by email Literature Review of famitinib trials Research Report on famitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Rilvegostomig Alpha, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-09 |
| Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer Retlirafusp alfa Injection, Famitinib, AG - Pancreatic Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 88 | 2026-08-31 | 2026-09-11 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma SHR-1701, Famitinib - Melanoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 70 | 2026-04-01 | 2026-04-08 |
| Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer Fluzoparib - Ovarian Cancer | Phase 2 | Not yet recruiting | Jinhua Zhou | 43 | 2026-02-28 | 2026-02-03 |
| A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer Camrelizumab, Famitinib - Cervical Cancer Metastatic, Cervical Cancer Recurrent | Not yet recruiting | Qi Zhou | 1300 | 2025-12-30 | 2025-12-05 | |
| A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer fuzuloparib, Famitinib, SHR-1701 - Ovarian Cancer | Phase 2 | Not yet recruiting | Qinglei Gao | 104 | 2025-12-30 | 2026-01-21 |
| A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer Famitinib + Camrelizumab - Cervical Cancer Metastatic, Cervical Cancer Recurrent | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2025-11-30 | 2025-11-18 |
| Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC Adebrelimab + Famitinib + Chemotherapy - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | First Affiliated Hospital Xi'an Jiaotong University | 24 | 2025-10-30 | 2026-08-31 |
| Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. SHR-1701, Famitinib, Cryoablation - Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 36 | 2025-09-01 | 2025-08-28 |
| Neoadjuvant SNF Precision Therapy Phase III Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC) - Neoadjuvant Therapy | Phase 3 | Recruiting | Fudan University | 404 | 2025-04-08 | 2025-06-06 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab HRS-1167, Famitinib, Camrelizumab - BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 130 | 2024-09-30 | 2024-12-12 |
| Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Baohui Han | 80 | 2024-04-01 | 2024-03-27 |
| Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure Adibelimab - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 40 | 2024-03-30 | 2024-03-29 |
| A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. adebrelimab, famitinib, chemotherapy - Extensive-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Harbin Medical University | 40 | 2024-03-15 | 2024-03-12 |
| Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer 20 mg Famitinib & 1200 mg Adebrelimab - Thyroid Cancer | Phase 2 | Unknown | Ruijin Hospital | 67 | 2023-12-01 | 2023-11-28 |
| A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy - TNBC - Triple-Negative Breast Cancer | Phase 3 | Recruiting | Fudan University | 424 | 2023-08-20 | 2024-02-21 |
| FUSCC Refractory TNBC Platform Study (FUTURE2.0) A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab with famitinib, B1: TROP2 ADC - Triple-negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 120 | 2023-03-30 | 2026-04-16 |
| Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin - Triple-Negative Breast Cancer | Phase 3 | Recruiting | Fudan University | 223 | 2023-03-17 | 2024-02-06 |
Showing 20 of 54. Sign in to see all of them.
Triple Negative Breast Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Gastrointestinal Stromal Tumors (2) · Melanoma (2) · Nasopharyngeal Carcinoma (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Transitional Cell (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1)
Jiangsu HengRui Medicine Co., Ltd. (22) · Fudan University (12) · Tianjin Medical University Cancer Institute and Hospital (2) · Baohui Han (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Harbin Medical University (1) · Henan Cancer Hospital (1) · Jinhua Zhou (1) · Peking University Cancer Hospital & Institute (1) · Peking University People's Hospital (1) · Qi Zhou (1) · Qian Chu (1) · Qinglei Gao (1) · Ruijin Hospital (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1)
China (45)
Ruihua Xu, M.D (2) · Zhimin Shao, M.D. (2) · Baohui Han (1) · Dingwei Ye, MD (1) · Feng Cheng, MD (1) · Hui Guo (1) · Jianhui Ma, M.D (1) · Jianming Xu, MD (1) · Jinwan Wang, M.D (1) · Jinwan Wang, M.D. (1) · Jun Guo, MD (1) · Li Zhang, M.D. (1) · Lin Shen, M.D (1) · Lin Wu (1) · Min Yan (1)
PMID 29273089, PMID 33570247, PMID 35017154, PMID 35247906, PMID 35337339, PMID 35537782, PMID 36107220, PMID 36481736, PMID 37415845, PMID 38211606, PMID 38362377, PMID 38388167, PMID 39872476, PMID 40561369, PMID 42165088, PMID 42421507